<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006243</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02359</org_study_id>
    <secondary_id>MC9973</secondary_id>
    <secondary_id>CDR0000068171</secondary_id>
    <nct_id>NCT00006243</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma</brief_title>
  <official_title>Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studies vaccine therapy and sargramostim in treating
      patients with stage IV malignant melanoma. Vaccines made from melanoma peptides or antigens
      may help the body build an effective immune response to kill tumor cells. Colony-stimulating
      factors, such as sargramostim, increase the number of white blood cells and platelets found
      in bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be
      an effective treatment for malignant melanoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the immunological effects of immunization protocols utilizing MART-1:27-35
      (MART-1:27-35 peptide vaccine), tyrosinase (tyrosinase peptide) or gp-100 (gp100 antigen)
      peptides suspended in incomplete Freund's adjuvant (IFA) in the presence of two different
      concentrations of sargramostim (GM-CSF).

      II. Define the safety and toxicity profile of an immunization protocol utilizing varying
      concentrations of MART-1:27-35, tyrosinase and gp-100 peptides suspended in IFA in the
      presence of two different concentrations of GM-CSF.

      III. Collect preliminary data on therapeutic efficacy as it relates to parameters of immune
      function in patients with stage IV malignant melanoma.

      OUTLINE: Patients are randomized to 1 of 3 treatment arms.

      ARM I: Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen
      admixed in incomplete Freund's adjuvant subcutaneously (SC) on day 1 of weeks 0, 3, 6, 9, 12,
      and 24.

      ARM II: Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen
      admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks
      0, 3, 6, 9, 12, and 24.

      ARM III: Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen
      admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks
      0, 3, 6, 9, 12, and 24.

      In all arms, treatment may repeat every 3 months for up to 18 months in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for up to 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in tumor antigen peptide specific immune responses</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Plots of the percent changes in these factors from their pretreatment levels against time will be constructed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of hematologic and non-hematologic toxicities observed using the Common Toxicity Criteria (CTC) version 2.0</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of objective responses (complete response [CR] and partial response [PR]) observed</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
    <other_name>TYRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1:27-35 peptide vaccine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
    <other_name>gp100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
    <other_name>IFA</other_name>
    <other_name>ISA-51</other_name>
    <other_name>Montanide ISA 51</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (vaccine therapy)</arm_group_label>
    <arm_group_label>Arm II (vaccine therapy and lower-dose sargramostim)</arm_group_label>
    <arm_group_label>Arm III (vaccine therapy and higher-dose sargramostim)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human leukocyte antigen (HLA)-A2 positive

          -  Histologic proof of stage IV malignant melanoma with measurable disease

          -  Absolute neutrophil count (ANC) &gt;= 1500

          -  Platelets (PLT) &gt;= 100,000

          -  Alkaline phosphatase (Alk phos) =&lt; 3 x upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) =&lt; 3 x ULN

          -  Creatinine (Creat) =&lt; 1.5 x ULN

          -  Hemoglobin (Hgb) &gt; 9.0

          -  Ability to provide informed consent

          -  Willingness to return to a Mayo Clinic institution for follow-up

          -  Life expectancy &gt;= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

        Exclusion Criteria:

          -  Uncontrolled or current infection

          -  Prior immunization with differentiation antigen peptides

          -  Known standard therapy for the patient's disease that is potentially curative or
             proven capable of extending life expectancy

          -  Any of the following prior therapies:

               -  Chemotherapy =&lt; 4 weeks

               -  Mitomycin C/nitrosoureas =&lt; 6 weeks

               -  Immunotherapy =&lt;4 weeks

               -  Biologic therapy =&lt; 4 weeks

               -  Radiation therapy =&lt; 4 weeks

               -  Radiation to &gt; 25% of bone marrow

          -  Failure to fully recover from effects of prior chemotherapy regardless of interval
             since last treatment

          -  New York Heart Association classification III or IV

          -  Seizure disorder

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Women of childbearing potential or their sexual partners who are unwilling to
                  employ adequate contraception (condoms, diaphragm, birth control pills,
                  injections, intrauterine device [IUD], surgical sterilization, subcutaneous
                  implants, or abstinence, etc.)

          -  Other concurrent chemotherapy, immunotherapy, or radiotherapy

          -  Active psychiatric disorder requiring medications (anti-psychotics)

          -  Known central nervous system metastases or carcinomatous meningitis

          -  History of other malignancy in last 5 years with the exception of basal cell or
             squamous cell carcinoma of the skin treated with local resection only (it is
             impossible to predict the effect of study treatment on other, potentially dormant
             malignant diseases)

          -  Known immune deficiency (patients with known immune deficiencies will likely not be
             able to mount an immune response to the study vaccine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetomir Markovic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>May 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

